| GlaxoSmithKline AG - Relvar Ellipta 184/22 mcg, Einzeldosiertes Pulver zur Inhalation |
| 62969 | | 02 | | Relvar Ellipta 184/22 mcg | | Einzeldosiertes Pulver zur Inhalation | | R03AK10 | | Vilanterol and Fluticasone Furoate | | 09.01.2014 | | |
|
| Composition |
| fluticasoni furoas 184 µg, vilanterolum 22 µg ut vilanteroli trifenatas, magnesii stearas, lactosum monohydricum, ad pulverem pro dosi, doses pro vase 30. |
| Packungsbestandteile |
| Einzeldosiertes Pulver zur Inhalation | | | | | | | | Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 184 µg | | Vilanterolum | 22 µg |
| | BAG: Principe actif | Concentr. |
|---|
| Fluticasoni Furoas | 184 mcg | | Vilanterolum | 22 mcg |
| | | | Agents auxilliaires |
|---|
| Lactose Monohydrate | | Magnesii Stearas |
| |
|
|
